In last trading session, Acumen Pharmaceuticals Inc (NASDAQ:ABOS) saw 0.4 million shares changing hands with its beta currently measuring -0.01. Company’s recent per share price level of $1.39 trading at $0.01 or 0.72% at ring of the bell on the day assigns it a market valuation of $83.51M. That closing price of ABOS’s stock is at a discount of -266.19% from its 52-week high price of $5.09 and is indicating a premium of 7.91% from its 52-week low price of $1.28.
For Acumen Pharmaceuticals Inc (ABOS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.37 in the current quarter.
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) trade information
Upright in the green during last session for gaining 0.72%, in the last five days ABOS remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.39 price level, adding 8.55% to its value on the day. Acumen Pharmaceuticals Inc’s shares saw a change of -19.19% in year-to-date performance and have moved -4.79% in past 5-day. Acumen Pharmaceuticals Inc (NASDAQ:ABOS) showed a performance of -20.57% in past 30-days.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 80.14% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -403.6% in reaching the projected high whereas dropping to the targeted low would mean a loss of -403.6% for stock’s current value.
Acumen Pharmaceuticals Inc (ABOS) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -54.03% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -46.30% while estimates for its earnings growth in next 5 years are of -18.56%.
Acumen Pharmaceuticals Inc (NASDAQ:ABOS)’s Major holders
RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at ABOS for having 14.93 million shares of worth $36.14 million. And as of 2024-06-30, it was holding 24.965 of the company’s outstanding shares.
The second largest institutional holder is SANDS CAPITAL VENTURES, LLC, which was holding about 3.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.713 of outstanding shares, having a total worth of $8.27 million.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Health Care are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.15 shares of worth $1.59 million or 1.91% of the total outstanding shares. The later fund manager was in possession of 1.14 shares on Dec 31, 2024 , making its stake of worth around $1.58 million in the company or a holder of 1.90% of company’s stock.
